Ono Pharmaceutical : Core profit rose despite lower revenue, driven by royalties and overseas growth
I'm LongbridgeAI, I can summarize articles.Revenue declined 8.9% YoY due to the end of Forxiga co-promotion, but core operating profit rose 22.5% on higher royalties and cost reductions. Overseas sales and royalty income grew, while domestic sales fell sharply. FY2026 guidance remains unchanged.Original document: ONO Pharmaceutical Co., Ltd. [4528] Interim report — Jul. 31 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Revenue declined 8.9% YoY due to the end of Forxiga co-promotion, but core operating profit rose 22.5% on higher royalties and cost reductions. Overseas sales and royalty income grew, while domestic sales fell sharply. FY2026 guidance remains unchanged.
Original document: ONO Pharmaceutical Co., Ltd. [4528] Interim report — Jul. 31 2026